Annie Marques*
Coronary artery disease remains a leading cause of mortality and morbidity worldwide. The conventional treatment approaches often face limitations such as low drug bioavailability, off-target effects and inadequate therapeutic outcomes. Nanotechnology has emerged as a promising solution to address these challenges by enabling targeted drug delivery to the affected site, thereby enhancing therapeutic efficacy while minimizing systemic side effects. This article reviews recent advancements in nanotechnology-based drug delivery systems for CAD treatment, highlighting the strategies to improve drug selectivity, stability and controlled release. Furthermore, the potential benefits and challenges of these novel approaches are discussed, along with their potential to revolutionize the management of CAD.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 